The number of deaths after six weeks was 619 (6.4%) in the lisinopril group and 693 (7.2%) in the control group.
The number of deaths in the first week was 374 (3.9%) in the lisinopril group and 437 (4.5%) in the control group.
In the lisinopril group the number of patients with cardiac insufficiency was 462 (4.9%), re-infarction 303 (3.2%), and post-infarct angina 1,985 (21%). In the control group the number of patients with cardiac insufficiency was 454 (4.8%), re-infarction 292 (3.1%), and post-infarct angina 1,909 (20.2%).
In the lisinopril group the number of patients with cardiac shock was 234 (2.5%), persistent hypotension 852 (9%), renal disorder 226 (2.4%), ventricular fibrillation 232 (2.5%), and advanced atrioventricular block 503 (5.3%). In the control group the number of patients with cardiac shock was 208 (2.2%), persistent hypotension 351 (3.7%), renal disorder 106 (1.1%), ventricular fibrillation 251 (2.7%), and advanced atrioventricular block 445 (4.7%).
Length of hospital stay was not significantly different: 15.1 days (+/- 6.7 days) in the lisinopril group and 14.9 days (+/- 6.8 days) in the control group.
Death rates both within the first weeks and after 6 weeks were significantly lower in the lisinopril group than in the control group.
Cases of persistent hypotension and renal disorder were significantly more numerous in the lisinopril group.
The other outcomes were not significantly different.